Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

358.77
-7.1700-1.96%
Post-market: 358.770.00000.00%19:30 EDT
Volume:351.45K
Turnover:127.09M
Market Cap:40.90B
PE:64.19
High:371.09
Open:367.94
Low:358.32
Close:365.94
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:80.95M
Volume Ratio:0.92
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.90
PE(LYR):145.25

Loading ...

BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia

Simply Wall St.
·
Aug 15

JPMorgan Chase & Co. Increases Stake in BEONE MEDICINES by Over 4.1 Million Shares at Approximately HKD 219.79 Each

Stock News
·
Aug 14

Beone Medicines Awards Over 40,000 Restricted Stock Units to Employees

Stock News
·
Aug 13

Pharmaceutical Rally Continues: Gan&Lee Pharmaceuticals Hits Limit-Up, Beone Medicines Logs 6-Day Winning Streak; Huabao Funds' HK Medical and Innovation Drug ETFs Rise for Third Consecutive Session

Deep News
·
Aug 11

Beone Medicines : Jefferies Raises Target Price to $395 from $388

THOMSON REUTERS
·
Aug 11

CICC Retains Outperform Rating on BeiGene (06160) with HKD 266 Price Target

Stock News
·
Aug 11

BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development

Stock News
·
Aug 11

BeOne Medicines partners with Revolution Medicines for clinical development

TIPRANKS
·
Aug 10

BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating

Stock News
·
Aug 10

Goldman Sachs Competitor Adjusts BeOne Medicines Target Upward, Bullish Ratings Maintained

Deep News
·
Aug 09

BEONE MEDICINES Confirms External CMO Supply for Baiyueda, All Processes On Schedule

Deep News
·
Aug 07

BEONE MEDICINES: Approximately 95% of Pancreatic Cancer Cases Show KRAS Mutation, Around 20% Exhibit MTAP Deletion, Enabling Easy Identification of Overlapping Patient Groups

Deep News
·
Aug 07

BEONE MEDICINES Reports BRUKINSA Captures Over Half of New CLL/SLL Patient Share

Deep News
·
Aug 07

Beigene's GPC3x4-1BB Candidate Moves From Phase 1 to a Potential Pivotal Phase 2 Study in About 19 Months

Deep News
·
Aug 07

BEONE MEDICINES Halts Initial KRAS Inhibitor Project but Remains Active in RAS Field

Deep News
·
Aug 07

BEONE MEDICINES Plans to Unveil Preliminary CEA ADC Findings for Non-Small Cell Lung Cancer, Including Both Squamous and Non-Squamous Cases

Deep News
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.49% in Regular Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.48% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.16% Overnight, Q2 Earnings Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

CLSA Maintains Outperform Rating on BEONE MEDICINES, Raises Price Target to HK$321.70

Deep News
·
Aug 07